Linda Hakes, Ph.D.

Dr. Linda Hakes has more than 40 years of experience in the pharmaceutical industry, having worked for notable companies including Glaxo, Marion Merrell Dow, Celltech, Eli Lilly, Schwarz Pharma AG, and UCB Biosciences. Her experience covers pharmaceutical development, preclinical development, clinical trial supplies, quality assurance, and project leadership. Since 2016, she has embarked on a career as an independent consultant, specializing in pharmaceutical development and strategic planning.

 

Linda is a former member of the Assembly of the Royal Pharmaceutical Society and a past Chairman of the Academy of Pharmaceutical Sciences (APS). She remains a member of the APS Advisory Board. She is a former Vice President of the International Pharmaceutical Federation (FIP) and has been a visiting Professor at Sunderland University. Linda is a Fellow of both the Royal Pharmaceutical Society and FIP.

 

Bobby Singh, Ph.D.

CEO of Corsair Pharma, Dr. Bobby Singh, has been at the forefront of innovation in the biopharmaceutical sector. He has contributed to the advancement of clinical operations, regulatory affairs, intellectual property, research and development, and quality systems. His strategic vision and leadership were instrumental in pivotal developments, including the execution of corporate partnerships and successful fundraising activities, culminating in a notable Initial Public Offering (IPO).

Bobby led the development of two technology platforms: Corplex™ and MicroCor® for transdermal delivery of small and large molecules using biodegradable microstructures. His efforts have led to the approval of three Abbreviated New Drug Applications (ANDA) and two New Drug Applications (NDA).